சிகிச்சைகள் மற்றும் பரிசோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Industry News: Merck acquires AmpTec to expand mRNA capabilities for vaccines, treatments and diagnostics
Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing Merck portfolio
11 Jan 2021
Merck, a leading science and technology company, has announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.
“The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lip ....

Stefan Oschmann , Peter Scheinert , Guido Krupp , Industry News , Executive Board , Life Science , Merck Acquires Amptec To Expand Mrna Capabilities For Vaccines , Treatments And Diagnostics The Life Science Business Of Merck Kgaa , Operates As Milliporesigma In The Us And Canada Merck Acquires Amptec To Expand Mrna Capabilities For Vaccines , Treatments And Diagnostics , வழிகாட்டி க்ரப் , தொழில் செய்தி , நிர்வாகி பலகை , வாழ்க்கை அறிவியல் , சிகிச்சைகள் மற்றும் பரிசோதனை ,